CITANEST PLAIN (prilocaine hydrochloride) · AstraZeneca
CITANEST PLAIN is FDA-approved to treat 2 conditions (same as PRILOCAINE HYDROCHLORIDE).
Details
- Status
- Discontinued
- First Approved
- 1965-11-18
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CITANEST PLAIN Approval History
What CITANEST PLAIN Treats
2 indicationsCITANEST PLAIN is approved for 2 conditions since its original approval in 1965. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Local anesthesia for dental procedures
- Nerve block and infiltration in dentistry
Same approved indications as PRILOCAINE HYDROCHLORIDE (same active ingredient).
AstraZeneca's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CITANEST PLAIN FDA Label Details
Indications & Usage
CITANEST PLAIN is FDA-approved to treat 2 conditions — same approved indications as PRILOCAINE HYDROCHLORIDE.
Track CITANEST PLAIN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.